FRONTIER CAPITAL MANAGEMENT CO LLC
Position in RARE — Ultragenyx Pharmaceutical Inc.
CIK 351173
Boston, MA
Position in RARE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$95,092,583
+$49,187,321 QoQ
Shares Held
2,847,936
+30.0% QoQ
Ownership
2.89%
of shares outstanding
% of Portfolio
0.89%
of 13F equity value
Holder Rank
#10
of 310 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 46%
Shared 0%
None 54%
Common Shares in RARE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FRONTIER CAPITAL MANAGEMENT CO LLC holds $975,847,387 across 22 Biotechnology names. RARE ranks #2 (9.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
1,373,057 | $102,265,285 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
This page
|
2,847,936 | $95,092,583 | |
| 3 | KYMR |
Kymera Therapeutics, Inc.
|
740,866 | $84,955,104 | |
| 4 | INSM |
INSMED Inc
|
795,242 | $84,788,702 | |
| 5 | PVLA |
Palvella Therapeutics, Inc.
|
478,833 | $73,175,259 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
277,279 | $66,815,920 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
254,280 | $62,240,115 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
3,070,740 | $57,269,301 |
All Filings in RARE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $95,092,583 | 2,847,936 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $45,905,262 | 2,191,182 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $45,196,932 | 1,965,084 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $32,158,467 | 1,069,098 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $19,105,871 | 525,464 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||